Viropharma (VPHM -7%) finishes lower after its Q1 earnings missed on the top line. Net sales...

|By:, SA News Editor

Viropharma (VPHM -7%) finishes lower after its Q1 earnings missed on the top line. Net sales declined Q/Q, which was driven by a decline in Vancocin revenues due to generic competition. Vancocin net sales during the three months were $4M compared to $66M in the year prior. The company also reaffirmed FY13 revenues towards the low end of estimates, expecting to earn between $440M - $465M, versus the Street consensus of $464M.